Drug Approval | June 24, 2022
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Bringing next-gen cannabinoid therapeutics to cancer patients
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Subscribe To Our Newsletter & Stay Updated
